Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Samsung C&T operates as a diversified conglomerate with an active life sciences division. Samsung Biologics' CDMO production capacity exceeds 600 kiloliters, and Samsung Bioepis has launched seven biosimilar products. Samsung C&T has made strategic investments in emerging biotech companies including Jaguar Gene Therapy, C2N Diagnostics, and GRAIL.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Samsung C&T Corporation.